Aditxt, Inc.
- Open
- 0.01
- Day high
- 0.01
- Day low
- 0.01
- Prev close
- 0.01
- Volume
- 16.5M
- Mkt cap
- $5427
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -0.0
- P/S
- 0.4
- Yield
- —
- Per share
- —
- ▲Insiders net buying $28K over the last 3 months (9 open-market buys, 12 sales)
- ◆Cluster buying — multiple insiders bought within days
Aditxt, Inc. (ADTX) is a Healthcare company listed on NASDAQ. The stock is down 100% over the past year. Over the trailing 3 months, insiders filed 9 open-market buys and 12 sales (SEC Form 4).
Aditxt, Inc. (ADTX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ADTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 20, 2026 | $-2245536000.00 | $-2.06 | +100.0% | $12159 | -98.8% |
| Nov 17, 2025 | — | $-73.15 | — | $748 | — |
| Aug 14, 2025 | — | $-392.05 | — | $1004 | — |
| May 15, 2025 | — | $-8.12 | — | $1018 | — |
| Mar 24, 2025 | $-26400.00 | $-100.71 | +99.6% | $3175 | -99.3% |
| Nov 18, 2024 | $-27400.00 | $-27767.50 | -1.3% | $6854 | -98.2% |
| Aug 19, 2024 | $-26900.00 | $-41900.00 | -55.8% | $44276 | -87.3% |
| May 20, 2024 | $-33300.00 | $-91400.00 | -174.5% | $79680 | -75.5% |
| Nov 14, 2023 | $-59900.00 | $-487699.97 | -714.2% | $124486 | -50.2% |
| Aug 14, 2023 | $-1156000.00 | $-367999.97 | +68.2% | $220978 | -38.1% |
| May 15, 2023 | $-2.78 | $-1.31 | +52.9% | $218415 | -36.3% |
| Nov 14, 2022 | $-999999.94 | $-2107999.75 | -110.8% | $323125 | -3.4% |
ADTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 25, 2026 | Takeover Time 2026 LLC10 percent owner | Sell | 3,420,439 | $0.02 |
| Jun 24, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 5,120,480 | $0.02 |
| Jun 24, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 7,340,178 | $0.01 |
| Jun 18, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 3,132,480 | $0.01 |
| Jun 18, 2026 | DRW Securities, LLC10 percent owner | Sell | 126,772 | $0.01 |
| Jun 17, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 2,114,344 | $0.01 |
| Jun 16, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 4,252,767 | $0.02 |
| Jun 15, 2026 | BANK OF AMERICA CORP /DE/10 percent owner | Sell | 15 | $0.01 |
| Jun 15, 2026 | BANK OF AMERICA CORP /DE/10 percent owner | Buy | 3 | $0.01 |
| Jun 15, 2026 | BANK OF AMERICA CORP /DE/10 percent owner | Buy | 1 | $0.02 |
| Jun 12, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 2,833,463 | $0.01 |
| Jun 11, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 725,330 | $0.02 |
| Jun 11, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 1,423,493 | $0.05 |
| Jun 11, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 878,659 | $0.03 |
| Jun 10, 2026 | Gong Sandie10 percent owner | Sell | 100,000 | $0.07 |
Source: ADTX SEC Form 4 filings, latest Jun 25, 2026. For informational purposes only — not investment advice.
See the full ADTX insider & 13F page →Aditxt, Inc. company profile
Overview
Aditxt, Inc. (NASDAQ:ADTX) is a Richmond, Virginia-based biotechnology company that was incorporated in 2017 and went public in June 2020. Originally known as ADiTx Therapeutics, Inc., the company changed its name to Aditxt, Inc. in July 2021. The company focuses on developing innovative technologies to improve immune system health through immune mapping and reprogramming approaches. Aditxt operates in the highly specialized field of immunotherapy, working on both diagnostic tools and therapeutic interventions that could potentially transform how immune-related conditions are understood and treated.
Business
Aditxt operates in the biotechnology sector, specifically focusing on immune system technologies and immunotherapy development. The company's work centers around two main technological platforms that address different aspects of immune system health and dysfunction. The company's primary diagnostic offering is AditxtScore, a proprietary immune profiling technology that functions as a comprehensive immune system assessment tool. This platform allows individuals to understand, manage, and monitor their immune profiles by providing detailed insights into their immune system's current state and potential vulnerabilities. The technology aims to inform users about potential attacks on their immune system or situations where their immune system might be attacking their own body, which is characteristic of autoimmune diseases. This represents a significant advancement in personalized medicine, as traditional immune system assessments are often limited and don't provide the comprehensive picture that AditxtScore aims to deliver. On the therapeutic side, Aditxt is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology platform that represents a novel approach to treating immune system disorders. This technology mimics the body's natural process of inducing tolerance to its own tissues, which is crucial for preventing autoimmune reactions. The ADi platform works by utilizing the natural cellular process of apoptosis (programmed cell death) to teach the immune system to recognize and tolerate specific antigens, thereby preventing harmful immune responses. The company is developing ADi products for several therapeutic areas including organ transplantation (particularly skin grafting), autoimmune diseases, and allergies. In organ transplantation, the technology could potentially reduce or eliminate the need for lifelong immunosuppressive drugs by training the recipient's immune system to accept the transplanted tissue. For autoimmune diseases, the platform could help retrain the immune system to stop attacking the body's own tissues, while for allergies, it could reduce hypersensitive immune responses to environmental triggers.
Revenue model
Aditxt's business model is currently in the early development stage typical of biotechnology companies, with revenue generation primarily coming from research collaborations and licensing agreements rather than commercial product sales. The company has licensing agreements with prestigious institutions including Loma Linda University and Leland Stanford Junior University, which provide access to foundational intellectual property and research capabilities. The company's revenue has been minimal and inconsistent, reflecting its pre-commercial status. In fiscal year 2024, total revenue was approximately $134,000, down from $645,000 in 2023 and $934,000 in 2022. This revenue likely comes from research grants, collaboration payments, or early-stage licensing fees rather than product sales, as neither AditxtScore nor ADi products appear to be commercially available yet. The primary customers for Aditxt's future products would include healthcare providers, hospitals, transplant centers, and potentially direct-to-consumer markets for the diagnostic AditxtScore platform. For the therapeutic ADi products, the customer base would primarily be healthcare institutions, specialty clinics focusing on autoimmune diseases, transplant centers, and allergy treatment facilities. Several factors could significantly impact Aditxt's future margins and revenue potential. Positive factors include the growing awareness and prevalence of autoimmune diseases, increasing demand for personalized medicine approaches, the substantial unmet medical need in organ transplantation, and the potential for premium pricing if the technologies prove effective. However, negative factors include the extremely high costs and lengthy timelines associated with biotechnology development, intense competition from established pharmaceutical companies, regulatory approval risks that could delay or prevent commercialization, and the significant capital requirements needed to fund clinical trials and bring products to market.
Competitive moat
Aditxt's competitive moat is currently weak and largely theoretical, based primarily on its intellectual property portfolio and early-stage technological approaches rather than proven market advantages. The company's potential moat rests on several factors that remain unproven in commercial applications. The company's licensing agreements with Loma Linda University and Stanford University provide access to foundational research and intellectual property, which could create some barriers to entry for competitors. Additionally, if the AditxtScore diagnostic platform and ADi therapeutic technology prove effective in clinical trials, the company could establish first-mover advantages in specific niches of immune profiling and tolerance induction. However, the biotechnology industry is characterized by intense competition from well-funded pharmaceutical giants, academic institutions, and other biotech companies working on similar immune system challenges. Large pharmaceutical companies have significantly more resources to develop competing technologies, conduct extensive clinical trials, and navigate regulatory approval processes. The field of immunotherapy is particularly crowded, with numerous established players like Gilead, Bristol Myers Squibb, and others having substantial head starts and proven track records. The company's current financial position also undermines its ability to build and maintain competitive advantages. With limited cash reserves and high burn rates, Aditxt faces significant challenges in funding the extensive research and development needed to bring its technologies to market before competitors develop similar or superior solutions. The regulatory approval process for both diagnostic and therapeutic products is lengthy and expensive, requiring sustained investment over many years. Without proven clinical efficacy data, established partnerships with major healthcare providers, or significant financial resources, Aditxt's moat remains highly speculative and vulnerable to competitive threats from better-funded and more established players in the immunotherapy space.
Risks & safety
Aditxt presents significant financial risk with minimal margin of safety for investors, reflecting the precarious position typical of early-stage biotechnology companies. • Cash burn and solvency risk: The company had only $476,000 in cash as of Q1 2025, while burning approximately $11.7 million in operating cash flow during the quarter. At this burn rate, the company faces immediate liquidity concerns and will likely need additional financing within months. • Debt and current liabilities: Total current liabilities of $15.2 million far exceed current assets of $1.2 million, resulting in a current ratio of just 0.08, indicating severe short-term liquidity problems. • Valuation metrics: With a market cap of approximately $3.3 million and minimal revenue ($1,018 in Q1 2025), traditional valuation metrics are largely meaningless. The company trades at extremely low absolute values, suggesting either deep value or distress. • Operational losses: The company has consistently reported significant losses, with net income of -$35 million in 2024 and -$32 million in 2023, showing no clear path to profitability. • Other considerations: The company's survival depends entirely on its ability to secure additional funding through equity raises, partnerships, or grants, making it highly dilutive to existing shareholders and extremely risky for new investors.
Recent development
Based on the available financial data, Aditxt appears to be in a critical phase of its development, though specific strategic initiatives are not clearly detailed in the provided information due to the absence of recent earnings call transcripts. The company's revenue pattern shows significant volatility, declining from $934,000 in 2022 to $645,000 in 2023, and further dropping to $134,000 in 2024, suggesting either a shift in business focus or challenges in maintaining research collaborations and licensing agreements. The dramatic increase in cash burn from approximately $18.6 million in 2023 to $16.8 million in 2024, while showing some improvement, still represents an unsustainable rate given the company's limited cash reserves. This suggests the company may be prioritizing critical research and development activities or clinical trial preparations, though specific program details are not available from the financial data alone. The company's balance sheet transformation over the recent periods indicates potential restructuring activities or significant changes in operational approach. The substantial decrease in total assets from $44.6 million in 2023 to $32.1 million in 2024 suggests either asset sales, write-downs, or other strategic repositioning efforts. Without access to management commentary through earnings calls, the specific strategic pivots, partnership developments, or clinical trial progressions that would typically characterize a biotechnology company's recent developments cannot be definitively identified from the financial statements alone.
ADTX company profile · for informational purposes only — not investment advice.
Track ADTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free